Cell No. : Cell Name
RCB1021 : T3M-4
update : 2020/09/24
|
| Comment | Pancreatic adenocarcinoma producing CEA. K-ras activated. Cell growth is slow. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, a prior written permission of the DEPOSITOR or the RIKEN BRC is necessary. |
| Remarks | |
| Order Form |
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC(cellbank.brc@riken.jp) regarding any kind of for-profit use.
|
|
|
Basic information
|
Depositor |
Okabe, Tetsuro
|
| Originator |
Okabe, Tetsuro
|
| Year of deposit |
1994
|
| Another name |
PANC
|
| Animal |
human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
64 years
|
| Tissue |
pancreas, lymph node meta
|
| Metastastatic ability |
Yes
|
| Classification |
cancer
|
| Year of origin |
1978
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Medium and additives |
|
HamF10 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% trypsin
|
Culture information
|
Passage ratio |
|
1 : 3 split
|
| SC frequency |
|
Subculture : once/2 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| STR(human) |
|
OK
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
57-130(50) : /58(4),59(5),60810),61(8),62(7)/
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
2
|
| User's Publication |
7
|
| User's Publication |
|
12080
Nishigaki T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hara H, Sugase T, Otsuru T, Saito Y, Tsujii S, Nomura T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Eguchi H, Yamasaki M, Mori M, Doki Y, Naka T.
Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.
Br. J. Cancer
2020
PubMed ID: 32152502
|
|
11646
Shichi Y, Sasaki N, Michishita M, Hasegawa F, Matsuda Y, Arai T, Gomi F, Aida J, Takubo K, Toyoda M, Yoshimura H, Takahashi K, Ishiwata T.
Enhanced morphological and functional differences of pancreatic cancer with epithelial or mesenchymal characteristics in 3D culture.
Sci Rep
2019
PubMed ID: 31350453
|
|
11960
Sasaki N, Hirabayashi K, Michishita M, Takahashi K, Hasegawa F, Gomi F, Itakura Y, Nakamura N, Toyoda M, Ishiwata T.
Ganglioside GM2, highly expressed in the MIA PaCa-2 pancreatic ductal adenocarcinoma cell line, is correlated with growth, invasion, and advanced stage.
Sci Rep
2019
PubMed ID: 31852956
|
|
4544
Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R.
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.
Nature
2017
546(7659):498-503
PubMed ID: 28607485
|
|
7761
Kahlert C, Bergmann F, Beck J, Welsch T, Mogler C, Herpel E, Dutta S, Niemietz T, Koch M, Weitz J.
Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer.
BMC Cancer
2011
11:275
PubMed ID: 21708005
|
|
5877
Yamamoto H, Okumura K, Toshima S, Mukaisho K, Sugihara H, Hattori T, Kato M, Asano S.
FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues.
Biol Pharm Bull
2009
32(7):1148-54
PubMed ID: 19571376
|
|
3717
Wada M, Yazumi S, Takaishi S, Hasegawa K, Sawada M, Tanaka H, Ida H, Sakakura C, Ito K, Ito Y, Chiba T.
Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines.
Oncogene
2004
23(13):2401-7
PubMed ID: 14743205
|
Back
Top
CELL BANK Website
